[Effects of cicletanine on plasma lipid metabolism. Mid-term open trial in hypertensive patients with normal blood lipids and hyperlipidemia].
Cicletanine, an antihypertensive drug heralding a new pharmacological family, was tested in a short-term open trial on 39 hypertensive patients with normal or increased lipidemia according to the W.H.O. criteria. This trial confirmed that the drug has excellent antihypertensive activity (normalization of blood pressure in 71.8% of the cases), is very well tolerated and has no unfavourable effect on lipid metabolism.